We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Clostridium Difficile Diagnostic Guidelines Updated

By LabMedica International staff writers
Posted on 08 Sep 2016
Print article
Image: The ImmunoCard C. difficile GDH rapid enzyme immunoassay (EIA) for the detection of Clostridium difficile common antigen glutamate dehydrogenase (GDH) in stool specimens (Photo courtesy of Meridian Bioscience).
Image: The ImmunoCard C. difficile GDH rapid enzyme immunoassay (EIA) for the detection of Clostridium difficile common antigen glutamate dehydrogenase (GDH) in stool specimens (Photo courtesy of Meridian Bioscience).
New guidelines on the best practice methods to diagnose Clostridium difficile infection (CDI) have been released and the latest document updates the original 2009, and includes recommendations concerning the use of new diagnostic technology such as nucleic acid amplification tests (NAAT).

The main objectives of this update of the guidance document are to summarize the currently available evidence concerning laboratory diagnosis of CDI and to formulate and revise recommendations to optimize CDI testing. This update is essential to improve the diagnosis of CDI and to improve uniformity in CDI diagnosis for surveillance purposes among European countries.

Scientists working under the auspices of The European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) identified 795 new studies, of which 693 were excluded and 102 selected for review. Of these, a further 61 were excluded, leaving 41 studies to be taken forward and used to support the new guidelines. Reasons for exclusion included incorrect or inconsistent reference testing, incorrect or inconsistent index testing, incorrect sample storage and incomplete sample testing. A total of 43 studies were also considered from the original meta-analysis, of which 28 were excluded and 15 taken forward.

Various laboratory assays available from commercial suppliers were assessed for their ability to diagnose CDI accurately. A reference test, typically cell cytotoxicity neutralization assay (CNNA) or toxigenic culture (TC) was used to investigate the accuracy of several tests that have emerged since 2009. These included enzyme immunoassays (EIA) that detect glutamate dehydrogenase or toxins A and B, and the new NAATs.

The strongest recommendations based on the evidence from all studies in the meta-analysis were: Samples to be tested for CDI should not be limited to cases in which a physician has specifically recommended; a rectal swab can be used for testing by (toxigenic) culture, NAAT or glutamate dehydrogenase (GDH) EIA in patients with apparent ileus (inactive bowel with no discernable bowel sounds); single, standalone tests are not reliable and should not be used: a two-step algorithm is necessary.

This two-step algorithm involves a combination of fast assays with follow up tests: Route one – the two-stage procedure should begin with either an NAAT or GDH EIA test. Negative tests should be treated as CDI negative, while positive tests should be followed up with a toxin A/B EIA test to confirm the result. Route two – the two-stage procedure should begin with both the GDH EIA test and the toxin A/B EIA test. If both are positive, CDI is likely to be present. If both are negative, CDI is unlikely to be present, however if GDH is positive and toxin A/B is negative, then the tests may optionally be followed up with an NAAT or TC test.

E.J. Kuijper a professor of experimental microbiology and senior author of the study said, “The new guidelines are intended for use among medical microbiologists, gastroenterologists, infectious disease specialists and infection control practitioners. Our aim is to not only improve diagnosis of CDI, but also to standardize the diagnostic process across Europe to allow for improved surveillance of the disease.” The study was published online on July 22, 2016, in the journal Clinical Microbiology and Infection.

Related Links:
The European Society of Clinical Microbiology and Infectious Diseases

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.